DOCSLIB.ORG

Welsh Pharmacy Review ISSUE 40 - 2019 Which We Can All Be a Part Of

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Welsh Pharmacy Review ISSUE 40 - 2019 Which We Can All Be a Part Of News Opinions Healthcare Pharmacy Welsh Review ISSUE 41 - 2019 PAEDIATRIC COELIAC DISEASE AN IDENTITY CRISIS? JUVENILE IDIOPATHIC ARTHRITIS The long-term outlook 2019 WELSH PHARMACY AWARDS The winners’ stories ASTHMA AND ALLERGY Improving patient empowerment URINARY INCONTINENCE And mental health AAH Complete Generics Best prices – best service – best on the market We realise that sourcing the best priced products can be stressful and time consuming. With AAH Complete Generics*, there’s no need to look anywhere else. Choose the market leading solution that offers you great product availability, reliable and fast service and the best price on your overall basket spend against the competition. If our basket is out, we give you money back. It’s that simple. There’s no better time to join AAH Complete Generics. Find out more at www.aah.co.uk, speak to your Account Manager or call 0247 643 2042 *Terms and conditions apply A McKesson Company WWW.WALESHEALTHCARE.COM WPR WELCOME ISSUE 41 – 2019 Medical Communications 2015 www.waleshealthcare.com www.pharmacy-life.co.uk Sarah Nelson Editor EDITOR [email protected] SARAH NELSON [email protected] DIRECTOR CHRIS FLANNAGAN [email protected] NATIONAL ACCOUNT MANAGER EDITOR'S LETTER NICOLA MCGARVEY [email protected] STUDIO MANAGER Welcome to the latest edition of Welsh Pharmacy DECLAN NUGENT [email protected] Review! ACCOUNTS MANAGER DONNA MARTIN [email protected] Aside from the long stretch of summer conversation (page 20). MANAGING DIRECTOR holidays – and, frankly, better music Get the know-how on all things BRIDGET MCCABE scene – if there’s one remnant of my vitamin D (page 48), and don’t miss [email protected] youth which I wish I’d tucked safely in our interview with Libby Dowling at IF YOU WISH TO CONTACT US BY TELEPHONE – 02890 999 441 my backpack to preserve for my later Diabetes UK, who shares tips for helping years, it would be that blissful lack of individuals with diabetes self-manage While every care has been taken in compiling this magazine to ensure that it is correct at the shame. responsibly (page 17). time of going to press, the publishers assume no responsibility for any effects from errors Be it tumbling off our bikes; As the All Wales Therapeutics & or omissions. The opinions of contributors are not necessarily those of the publisher. No part stumbling over our words during a school Toxicology Centre’s Clinical Director of this publication may be reproduced, stored in a retrieval system, or transmitted in any presentation; or simply saying no, it and founder, Professor Phil Routledge, form, or by any means, mechanical, electronic, photocopying, recording or otherwise seemed a lot easier to be unapologetic enters retirement after almost 40 years without the prior permission of Medical Communications 2015 Ltd. All rights reserved. when we were less accountable for of service in the NHS in Wales, read up Data Protection – Please note, your mailing details and copies of any articles supplied will ourselves and others. on his inspiring record of achievements be held on a database and may be shared with associated companies. Sometimes your details A huge perk of my job is that I get (page four), and stay social media-savvy may be obtained from, or made available to, external companies for marketing purposes. If to speak first-hand to practitioners as Dr Sally Old, Medico-Legal Adviser at you do not wish your details to be used for this purpose, please write to: Database Manager, and healthcare experts who are on the the Medical Defence Union, investigates Medical Communications 2015 Ltd, Suite 15, Martrey House, Units 2 & 3 Ravenhill Business frontlines of new research, as well as important issues for the sector to Park, Ravenhill Road, Belfast, BT6 8AW. Subscription: £120 a year the patients they’re driving change for. consider when using online platforms Please note our new address. However, with each issue and condition (page nine). investigated, we’re seeing familiar battle Before you go, make sure to catch lines drawn. up on the 2019 Welsh Pharmacy Patients feel silently consumed Conference’s happenings – featuring with embarrassment and shame, and a presentation by the Health Minister, News Opinions Healthcare Pharmacy health leaders are trying to break down Vaughan Gething – via our recap and Welsh stigmatising barriers by encouraging exclusive pictures (page 22). And check greater public discourse – something out the first half of our Welsh Pharmacy Review ISSUE 40 - 2019 which we can all be a part of. Awards winners and their incredible In this edition of WPR, we receive a merits (beginning on page 29). GET IT ON TIME PARKINSON’S AND glimpse of the problems which reluctance MEDICINE MANAGEMENT in opening up can pose – through the Happy reading! shocking number of prostate cancer patients receiving insufficient support ECZEMA How are families affected? for managing erectile dysfunction (page MENTAL HEALTH The drugs vs therapy debate DAY IN THE LIFE 38), and of the important need to propel Of a clinical trials pharmacist 2019 WELSH PHARMACY AWARDS urinary incontinence into mainstream Who will win? To access the previous editions of WPR online, visit @MEDCOMwales Medical Communications 2015 Ltd www.waleshealthcare.com/ previous-issue WPR | Sept 2019 | 1 ConvaTec have been helping people manage their stoma condition for over 30 years. All pouch users are unique and we have a solution to suit everyone. NO MORE CUT TO SIZE Custom Fit The only baseplate Mouldable Baseplate & which moulds to every individual Pouch Technology stoma The special Mouldable baseplates are available with our one and two piece stoma bags. Suitable for people who use drainable or closed pouches. SAMPLES AVAILABLE Product UK: 0800 282 254 Specialist We aim to complement the care you oer with our highly skilled team of nurses and medical professionals. Our specialist nurses are trained and experienced in caring for people in all aspects of continence and stoma care, our programmes are supported with advice on hydration, nutrition, exercise and mental health. WWW.WALESHEALTHCARE.COM CONTENTS ISSUE 41 – 2019 4 WORDS OF PRAISE The All Wales Therapeutics & Toxicology Centre have paid tribute to their Clinical Director and founder, Professor Phil Routledge, as he enters retirement 12 A WELCOME RELIEF An exploration of cannabidiol’s exciting paths of potential, and just why it’s reaching new heights of popularity 14 GREAT EXPECTATIONS » p.4 Faced with delays in treatment, how can we achieve early detection of paediatric coeliac disease? 20 A SENSE OF URGENCY Why we must steer the mental effects of urinary incontinence into mainstream conversation 22 2019 WELSH PHARMACY CONFERENCE From the presenters’ powerful messages to unmissable » p.45 » p.42 pictures, we recap the day 29 WELSH PHARMACY AWARDS Revel in the celebrations as we recognise the first half of this year’s winners 38 MEN’S HEALTH Help the many prostate cancer patients missing out on support for erectile dysfunction 40 DYSPHAGIA An overview of the medicine prescribing and administration » p.22 concerns for dysphagia management 42 JUVENILE IDIOPATHIC ARTHRITIS Delve into an arthritis diagnosis during childhood and adolescence – the clinical and patient perspectives 45 ASTHMA AND ALLERGY Shuaib Nasser, Consultant in Asthma and Allergic Disease, on why we must elevate patients’ understanding of potential triggers » p.14 WPR | Sept 2019 | 3 WWW.WALESHEALTHCARE.COM NEWS CLINICAL DIRECTOR OF THE ALL WALES THERAPEUTICS & TOXICOLOGY CENTRE RETIRES On 9th May, staff of the All Wales Therapeutics & Toxicology Centre (AWTTC) paid tribute to their Clinical Director and founder, Professor Phil Routledge, as he enters retirement after almost 40 years of service in the NHS in Wales. Professor Routledge was appointed a Consultant Clinical and teaching outputs from General Medicine, Respiratory Medicine, Pharmacologist in Cardiff & Vale University Health Board in 1981. Surgery, Wound Healing and Geriatric Medicine. Later, the current He worked with colleagues in Clinical Pharmacology and Pharmacy Cochrane Library was added as an extension to the Academic Centre, to bring the Welsh National Poisons Unit, the Yellow Card Centre plus undergraduate and postgraduate teaching facilities. These for Wales, and the Welsh Medicines Resource Centre to University contributed to Llandough Hospital’s reputation as a major teaching Hospital Llandough. He also established the Patient Access to hospital in Wales, leading to it being renamed the University Hospital Medicines Service and the Welsh Analytical Prescribing Support Unit. Llandough in 2008. All five organisations now form the AWTTC. The Academic Centre is now home for over 40 staff working for The AWTTC provides the All Wales Medicines Strategy Group the AWTTC. In recognition of Professor Routledge’s outstanding (AWMSG) with administrative and scientific support for the contributions to the University Hospital Llandough, NHS Wales, appraisals of new medicines, and to develop resources for prescribers Cardiff University and the AWTTC, the centre was renamed ‘The to optimise the use of current medicines. Professor Routledge had a Routledge Academic Centre’ on 9th May. fundamental role in delivering medicines services in NHS Wales, by For more information on the AWTTC, which Professor Routledge improving access for patients to clinical and cost-effective medicines. founded, visit www.awttc.org. He was also the longest serving Chair of the AWMSG (from 2006 – 2014). During his time as Chair, he commissioned the development of an All Wales single national inpatient prescription chart, which was endorsed by the UK’s Royal College of Physicians. ‘Phil has been an inspiration to our staff and a pleasure to work with for 25 years,’ commented Mrs Ruth Lang, Senior Liaison Manager, AWTTC. In 1992, Professor Routledge proposed developing the former nurses’ home at Llandough Hospital into a centre focused on teaching and research. With the Hospital Management Board’s agreement, the ‘Academic Centre’ was formed, showcasing high-quality research Professor Phil Routledge GPSAR is free to download for both iPhone and Android users.
Load more

Recommended publications
  • Register of GDP Sites 2019
    Register of GDP Sites 2019 Updated 16 August 2019 There are other sites authorised for wholesale dealing of veterinary medicinal products which do not appear on this register. These sites wholesale deal in both human and veterinary medicinal products and can be found on the MHRA section of GOV.UK: https://www.gov.uk/government/publications/human-and-vetinary-medicines- register-of-licensed-wholesale-distribution-sites-december-2014 Register of Authorised Wholesale Dealer Sites Authorisation Holder: WDA33618 ABBEYVET LLP 310 CHESTER ROAD, HARTFORD, NORTHWICH, CHESHIRE, CW8 2AB SITE ID: S0415 ABBEYVET LLP 310 CHESTER ROAD, HARTFORD, NORTHWICH, CHESHIRE, CW8 2AB SITE ID: S0010 ABBEYVET LLP SHERBURN ENTERPRISE PARK, SHERBURN IN ELMET, LEEDS, WEST YORKSHIRE, LS25 6NB Authorisation Holder: WDA8599 AGRIHEALTH (N.I.) LIMITED 9 SILVERWOOD INDUSTRIAL AREA, SILVERWOOD ROAD, LURGAN, CRAIGAVON, COUNTY ARMAGH, BT66 6LN SITE ID: S0015 AGRIHEALTH (N.I.) LIMITED 9 SILVERWOOD INDUSTRIAL AREA, SILVERWOOD ROAD, LURGAN, CRAIGAVON, COUNTY ARMAGH, BT66 6LN Authorisation Holder: WDA5097 ALBAVET LIMITED BUSINESS INCUBATOR OFFICE 21, MYREGORMIE PLACE, MITCHELSTON INDUSTRIAL ESTATE, KIRKCALDY, FIFE, KY1 3NA SITE ID: S0456 ALBAVET LIMITED BUSINESS INCUBATOR OFFICE 21, MYREGORMIE PLACE, MITCHELSTON INDUSTRIAL ESTATE, KIRKCALDY, FIFE, KY1 3NA SITE ID: S0525 CVS GROUP PLC CVS HOUSE, OWEN ROAD, DISS, NORFOLK, IP22 4ER Authorisation Holder: WDA5030 ALBERT E JAMES & SON LIMITED BARROW MILL BARROW STREET, BARROW GURNEY, BRISTOL, BS48 3RU SITE ID: S0303 ALBERT E JAMES &
    [Show full text]
  • United States Securities and Exchange Commission Form 10-K Shire Pharmaceuticals Group
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ፤ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 1999 អ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 0-29630 SHIRE PHARMACEUTICALS GROUP PLC (Exact name of registrant as specified in its charter) England and Wales (State or other jurisdiction (I.R.S. Employer of incorporation or organization) Identification No.) N.A. East Anton, Andover, Hampshire SP10 5RG England (Address of principal executive offices) (Zip Code) 44 1264 333455 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of exchange on which registered American Depository Shares, each representing Nasdaq National Market 3 Ordinary Shares, 5 pence nominal value per share Securities registered pursuant to Section 12(g) of the Act: None (Title of class) Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ፤ No អ Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the Registrant's knowledge, in definitive proxy or information statements incorporated by reference to Part III of this Form 10-K or any amendment to this Form 10-K.
    [Show full text]
  • Listing of Global Companies with Ongoing Government Activity
    COMPANY LINE OF BUSINESS TICKER A & A BIOTECHNOLOGY S C ADAM BURKIEWICZ MIKOLAJ BURKIEWICZ PHARMACEUTICAL PREPARATIONS A & A GLOBAL INDUSTRIES, INC. AUTOMATIC VENDING MACHINES, NSK A & J ENTERPRISES PHARMACEUTICAL PREPARATIONS A & S INTERNATIONAL 2000 S.R.L. PHARMACEUTICAL PREPARATIONS A & S PHARMACEUTICAL CORP. PHARMACEUTICAL PREPARATIONS A & T MARKETING INC. COMPUTER INTEGRATED SYSTEMS DESIGN, NSK A & T SYSTEMS, INC. TELEPHONE COMMUNICATION, EXCEPT RADIO A & Z PHARMACEUTICAL INC. PHARMACEUTICAL PREPARATIONS A A INTERNATIONAL PHARMACEUTICAL PREPARATIONS A AND V, INC. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC A AROGYA HARBALS PRIVATE LIMITED PHARMACEUTICAL PREPARATIONS A B ENTERPRISES PHARMACEUTICAL PREPARATIONS A B I HERBAL PRODUCTS MEDICINALS AND BOTANICALS, NSK A B S REMEDIES PRIVATE LIMITED MEDICINALS AND BOTANICALS, NSK A BEAT FOR YOUR FEET, INC. COIN-OPERATED LAUNDRIES AND CLEANING, NSK A BUCKHEAD BUS COMPANY LOCAL PASSENGER TRANSPORTATION, NEC A C C VIEIRA PROTESE ME MEDICINALS AND BOTANICALS, NSK A C CONSULTING PHARMACEUTICAL PREPARATIONS A C E DIAGNOSTICS & BIOTECH LIMITED PHARMACEUTICAL PREPARATIONS A C E PHARMACEUTICALS PHARMACEUTICAL PREPARATIONS A C PHARMACEUTICALS PRIVATE LIMITED PHARMACEUTICAL PREPARATIONS A CUT ABOVE LANDSCAPE LAWN AND GARDEN SERVICES A D C O MARKETING INC NONDURABLE GOODS, NEC, NSK A G HERBALS PRIVATE LIMITED MEDICINALS AND BOTANICALS, NSK A G PHARMACEUTICALS PHARMACEUTICAL PREPARATIONS A H C PHARMACAL, INC PHARMACEUTICAL PREPARATIONS A H SYSTEMS INC INSTRUMENTS TO MEASURE ELECTRICITY A HOUSE OF AYURVEDIC
    [Show full text]
  • CRR 446/2002 a Study of the Provision of Health and Safety Information in the Annual Reports of the Top UK Companies
    HSE Health & Safety Executive A study of the provision of health and safety information in the annual reports of the top UK companies Prepared by System Concepts Ltd for the Health and Safety Executive CONTRACT RESEARCH REPORT 446/2002 HSE Health & Safety Executive A study of the provision of health and safety information in the annual reports of the top UK companies Laura Peebles, Ansgar Kupper and Tanya Heasman System Concepts Ltd 2 Savoy Court Strand London WC2R 0EZ This report details the findings of a research project to investigate the quality and quantity of health and safety information found in the annual reports of the top UK companies. At present, publicly listed companies are not legally required to include health and safety matters in their annual reports. The current Health and Safety Commission (HSC) Strategy Statement, however, contains an action point which focuses on public reporting of health and safety issues by larger companies. The aim is to promote the reporting of health and safety information in company annual reports and to provide guidance that would allow reporting of such information to a common standard. To assist the HSC with this strategy, System Concepts were commissioned by the Health and Safety Executive (HSE) to undertake an investigation of the provision of health and safety information in company annual reports. The study comprised a series of steps. The main objectives of the study were: i) To determine the current level of reporting of health and safety issues in annual reports of the top UK companies ii) To determine the quality of health and safety information reported.
    [Show full text]
  • Rape Research
    Rape Research After scene 2, in Paulson‘s Tavern, Tara is left behind whilst it empties out. This is the perfect setting for Danni to tranquilise her with a date rape drug. This is quite a strong subject, and I felt like the whole group should put more research and get a greater understanding, so we know how to deal with the situation and portray it through our performance. Personally, I have never known anyone who has experienced this situation before, so to ensure that I would create a believable performance and reaction, I needed to get a greater understanding and look at interviews, dramas and information about date rape and the affect it has on people‘s lives. BBC Health – Rohypnol http://www.bbc.co.uk/health/physical_health/conditions/rohypnol.shtml What is Rohypnol? Rohypnol is the brand name of a medicine called flunitrazepam, and is one of the benzodiazepine class of sedative or tranquilizer drugs, of which ‗Valium‘ or diazepam is perhaps the best known. Rohypnol or flunitrazepam is 10 times more potent than diazepam. In the UK the drug is no longer used in the NHS but may be available on private prescription for those who need it (although it‘s generally felt that there are better alternatives). Its legal status in the UK is a class C drug, which means that it‘s illegal to possess flunitrazepam without a prescription. It‘s not legally available in the US, but as it is still made in some countries an illegal trade continues. Rohypnol rose to prominence as the date rape drug because it was colourless, odourless, tasteless and easily dissolved - ideal for spiking drinks undetected - and causes sedation or euphoria in approximately 20 to 30 minutes.
    [Show full text]
  • Cold Chain Distribution Conference and Exhibition Enhance Temperature Management for an Efficient Supply Chain
    SMi PRESENTS THE 9TH ANNUAL COLD CHAIN DISTRIBUTION CONFERENCE AND EXHIBITION ENHANCE TEMPERATURE MANAGEMENT FOR AN EFFICIENT SUPPLY CHAIN 2ND - 3RD DECEMBER 2014 | MARRIOTT REGENTS PARK, LONDON UK Sponsorship Manual www.coldchain-distribution.com “ A very well organised event. Professional team and well executed” Cold Chain Delegate 2013 9th annual Cold Chain Distribution Conference and Exhibition Drawing on 8 years of working within the Cold Chain Logistics industry, the SMi Group are delighted to announce their 9th annual Cold Chain Distribution Conference and Exhibition. Join this event and be part of a major networking opportunity providing intimate interaction with your peers, where you will hear case studies, presentations and round table discussions on the key issues surrounding the global healthcare cold chain distribution process and logistic requirements for various temperature sensitive healthcare products. Benefits of Attending: ● Benchmark and reflect on the implementation of the GDP directive with case studies from IATA, AbbVie and the Dutch Health Care Inspectorate ● Enhance your understanding of the challenges of transport qualification for temperature sensitive pharmaceutical products with a round table discussion led by Tony Wright, Managing Director, Exelsius Cold Chain Management and an opening address from Alan Dorling, Global Head – Pharmaceutical & Life Sciences, IAG Cargo ● Strengthen your supply chain through management and efficiency insights from Merck Serono and Genzyme ● In addition, Cold Chain Distribution
    [Show full text]
  • SHIRE PHARMACEUTICALS GROUP PLC (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2003 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 0-29630 SHIRE PHARMACEUTICALS GROUP PLC (Exact name of registrant as specified in its charter) England and Wales 98-0359573 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Hampshire International Business Park, Chineham, +44 1256 894 000 Basingstoke, Hampshire, England, RG24 8EP (Registrant’s telephone number, including area code) (Address of principal executive offices and zip code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of exchange on which registered American Depositary Shares, each representing 3 NASDAQ National Market Ordinary Shares 5 pence par value per share Securities registered pursuant to Section 12(g) of the Act: None (Title of class) Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ] Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the Registrant’s knowledge, in definitive proxy or information statements incorporated by reference to Part III of this Form 10-K or any amendment to this Form 10-K.
    [Show full text]
  • Merck & Co., Inc
    As filed with the Securities and Exchange Commission on February 28, 2017 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 _________________________________ FORM 10-K (MARK ONE) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2016 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 1-6571 _________________________________ Merck & Co., Inc. 2000 Galloping Hill Road Kenilworth, N. J. 07033 (908) 740-4000 Incorporated in New Jersey I.R.S. Employer Identification No. 22-1918501 Securities Registered pursuant to Section 12(b) of the Act: Name of Each Exchange Title of Each Class on which Registered Common Stock ($0.50 par value) New York Stock Exchange 1.125% Notes due 2021 New York Stock Exchange 0.500% Notes due 2024 New York Stock Exchange 1.875% Notes due 2026 New York Stock Exchange 2.500% Notes due 2034 New York Stock Exchange 1.375% Notes due 2036 New York Stock Exchange Number of shares of Common Stock ($0.50 par value) outstanding as of January 31, 2017: 2,745,571,067. Aggregate market value of Common Stock ($0.50 par value) held by non-affiliates on June 30, 2016 based on closing price on June 30, 2016: $159,263,000,000. Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
    [Show full text]
  • National Institute for Clinical Excellence
    Appendix C NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Single Technology Appraisal Lanadelumab for the long-term prevention of angioedema attacks in hereditary angioedema types I and II ID1268 Provisional matrix of consultees and commentators Consultees Commentators (no right to submit or appeal) Company General Shire Pharmaceuticals (Lanadelumab) All Wales Therapeutics and Toxicology Centre Patient/carer groups Allied Health Professionals Federation Action against Allergy Board of Community Health Councils in Action for sick children Wales Allergy UK British National Formulary Anaphylaxis Campaign, Genetic Care Quality Commission Alliance UK Department of Health, Social Services HAE UK Patient Support and Public Safety for Northern Ireland Let’s face it Healthcare Improvement Scotland Muslim Council of Britain Medicines and Healthcare Products NARA – The Breathing Charity Regulatory Agency National Children’s Bureau National Association of Primary Care Primary Immunodeficiency UK National Pharmacy Association South Asian Health Foundation NHS Alliance Specialised Healthcare Alliance NHS Confederation Scottish Medicines Consortium Professional groups Welsh Health Specialised Services Association of Respiratory Nurse Committee Specialists British Association of Dermatologists Possible comparator companies British Geriatrics Society A A H Pharmaceuticals (danazol) British Paediatric Respiratory Society Alliance Healthcare (danazol) British Society for Allergy & Clinical Mylan (danazol) Immunology
    [Show full text]
  • Case M.7818 – Mckesson / UDG Healthcare (Pharmaceutical Wholesale and Associated Businesses)
    Case M. 7818 – McKesson / UDG Healthcare (Pharmaceutical Wholesale and Associated Businesses) Only the English text is available and authentic. REGULATION (EC) No 139/2004 MERGER PROCEDURE Article 9(3) Date: 03.03.2016 In the published version of this decision, some information has been omitted pursuant to Article 17(2) of Council Regulation (EC) No 139/2004 concerning non-disclosure of business secrets and other confidential information. The omissions are shown thus […]. Where possible the information omitted has been replaced by ranges of figures or a general description. EUROPEAN COMMISSION Brussels, 3.3.2016 C(2016) 1474 final Public Version COMMISSION DECISION of 3.3.2016 relating to Article 9 of Regulation (EC) No 139/2004 referring to case M. 7818 – McKesson / UDG Healthcare (Pharmaceutical Wholesale and Associated Businesses) (Only the English text is authentic) COMMISSION DECISION of 3.3.2016 relating to Article 9 of Regulation (EC) No 139/2004 referring to case M.7818 – McKesson / UDG Healthcare (Pharmaceutical Wholesale and Associated Businesses) (Only the English text is authentic) THE EUROPEAN COMMISSION, Having regard to the Treaty on the Functioning of the European Union (the "TFEU")1, Having regard to the Agreement on the European Economic Area, and in particular Article 57 thereof, Having regard to Council Regulation (EC) No. 139/2004 of 20.1.2004 on the control of concentrations between undertakings2 (the "Merger Regulation"), and in particular Article 9(3) thereof, Having regard to the notification made by McKesson Corporation on 14 January 2016, pursuant to article 4 of the Merger Regulation, Having regard to the request of the United Kingdom of Great Britain and Northern Ireland’s Competition and Markets Authority of 22.01.2016, Whereas: (1) On 14 January 2016 the Commission received notification of a proposed concentration by which McKesson Deutschland GmbH & Co.
    [Show full text]
  • Register of GDP Sites 2015
    Register of GDP Sites 2015 Updated 5 May 2015 There are other sites authorised for wholesale dealing of veterinary medicinal products which do not appear on this register. These sites wholesale deal in both human and veterinary medicinal products and can be found on the Medicines and Healthcare products Regulatory Agency (MHRA) website: https://www.gov.uk/government/uploads/system/uploads/attachment _data/file/420985/Licensed_Wholesale_Distribution_Sites_2015.pdf Register of Authorised Wholesale Dealer Sites Authorisation Holder: WDA 33618 ABBEYVET LLP 310 CHESTER ROAD, HARTFORD, NORTHWICH, CHESHIRE CW8 2AB SITE ID: S0010 ABBEYVET LLP Sherburn Enterprise Park, Aviation Way, Sherburn in Elmet, Leeds, West Yorkshire, LS25 6NB SITE ID: S0415 ABBEYVET LLP 310 Chester Road, Hartford, Northwich, Cheshire CW8 2AB Authorisation Holder: WDA 8599 AGRIHEALTH (NI) LIMITED 9 SILVERWOOD INDUSTRIAL AREA, SILVERWOOD ROAD, LURGAN, CRAIGAVON, COUNTY ARMAGH, BT66 6LN SITE ID: S0015 AGRIHEALTH LIMITED 9 Silverwood Industrial Area, Silverwood Road, Lurgan, Craigavon, County Armagh, BT66 6LN Authorisation Holder: WDA 5097 ALBAVET LIMITED BUSINESS INCUBATOR OFFICE 21, MYREGORMIE PLACE, MITCHELSTON INDUSTRIAL ESTATE, KIRKALDY, FIFE KY1 3NA SITE ID: S0456 ALBAVET LIMITED Business Incubator Office 21, Myregormie Place, Mitchelston Industrial Estate, Kirkaldy, Fife KY1 3NA SITE ID: S0341 HENRY SCHEIN UK HOLDINGS LTD T/A HENRY SCHEIN ANIMAL HEALTH College Mains Road, Dumfries, Dumfries & Galloway DG2 0NU SITE ID: S0340 CENTAUR SERVICES LIMITED Centaur House, Torbay
    [Show full text]
  • Sheffield Teaching Hospitals NHS Foundation Trust Procurement Transparency Payments "February 2021"
    Sheffield Teaching Hospitals NHS Foundation Trust Procurement Transparency Payments "February_2021" Supplier Value Paid (PETTY CASH ACCOUNT) 3,132.92 1ST CALL MOBILITY LTD 13,338.00 3M UNITEK UK (ORTHODONTIC PRODUCTS) 432.00 4 WAYS HEALTHCARE LIMITED 7,660.00 40 SEVEN LTD 14,820.00 A AGARWAL 2,891.80 A CONDLIFFE 82.33 A CUMBERLIDGE LTD 5,846.23 A FORRESTER 2,501.80 A GRAFTON 1,375.72 A HILTON 96.77 A J STEFFAN 49.00 A KELLY 91.52 A L CLINICIAN LIMITED (RAJAK) 10,096.00 A LEWIS 488.18 A MARSHALL 45.52 A MARSHALL 1,572.60 A MAZAI 3,903.50 A MUSTAHAB 326.52 A RIDSDALE 7,259.05 A ROGERS 600.00 A SCHIEPATTI 57.83 A W BENT LTD 2,587.38 A-Z TEC MEDICAL LIMITED 260.40 A1-CBISS LTD 186.00 AAH PHARMACEUTICALS LTD 767,948.97 AAL LTD 89.39 AB SCIENTIFIC LTD 7,392.60 ABATRON LTD 583.20 ABBOTT LABORATORIES LTD 6,637.05 ABBOTT MEDICAL UK LTD 147,399.60 ABBOTT RAPID DIAGNOSTICS LTD 5,978.40 ABBVIE LTD 6,715.22 ABILITY SMART LIMITED 1,764.00 AC COSSOR & SON (SURGICAL) LTD 314.00 AC MAINTENANCE LTD 11,446.80 ACCIDENT SOLICITORS DIRECT 4,591.00 ACE JANITORIAL SUPPLIES LIMITED 15,776.24 ACES 324.00 ACORN ANALYTICAL SERVICES 2,289.00 ACORN INDUSTRIAL SERVICES LTD 2,459.15 ACROSTAK 2,071.20 ACTIVE DOCUMENTS LTD 2,676.00 ACUMED LTD 4,964.22 ADARE SEC LIMITED 804.30 Page 1 of 28 Supplier Value Paid ADEC DENTAL UK LTD 4,827.78 ADI ENVIRONMENTAL LTD 3,180.00 ADUR & WORTHING COUNCILS 146.66 ADVANCED ACCELERATOR APPLICATIONS 51,979.50 ADVANCED DIGITAL INNOVATION (UK) LTD 4,800.00 ADVANCED LABELLING LIMITED 1,209.23 ADVANCED STERILIZATION PRODUCTS (UK) LTD 13,666.44
    [Show full text]